TRMT6 and hepatocellular carcinoma: Similar to m6A and m5C, TRMT6 has been found to mediate the MYC, and also the PI3K/Akt signalling pathway in vitro, thereby downregulating m1A and affecting hepatocellular carcinoma (HCC) prognosis.8